Enesi partners with US army for solid dose Shigella vaccine

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/GiovanniCancemi)
(Image: Getty/GiovanniCancemi)

Related tags: Enesi Pharma, Walter Reed Army Institute of Research, Us, Shigella, Vaccine

Enesi announced it will use its proprietary formulation to produce a solid dose Shigella vaccine alongside the Walter Reed Army Institute of Research.

Developing a Shigella vaccine in solid dose formulation is a high-priority for the US army, Enesi Pharma said in a statement.

A Shigella infection, known as shigellosis, is an intestinal disease that results in diarrhoea, fever, and abdominal pain. Dysentery, though not exclusively caused by the Shigella bacteria, has long been an issue for combatants in war zones.

We were informed by a spokesperson of Enesi that the agreed partnership is not a licensing or commercialisation agreement and that any financial details will not be disclosed.

Instead, the partnership will see the Walter Reed Army Institute of Research (WRAIR) “provide its Invaplex Shigella vaccine to Enesi, and Enesi will create a solid dose formulation for delivery with its ImplaVax needle-free injector technology.

“WRAIR will test the solid dose product for biochemical integrity and immunogenicity in Shigella disease models. Data from the collaboration will be shared between Enesi and WRAIR, and could, pending the outcome, form the foundation of future commercial opportunities.”

Solid dose forms of vaccinations hold advantages over standard intravenous vaccine delivery through enhanced immune responses and the ease of delivery, according to Enesi’s website.

One significant benefit is also the reduced need, or even elimination, of cold-chain requirements, as the doses are not temperature sensitive to the same degree as traditional liquid formulations – a major aim within vaccine development​.

In terms of how the solid dose vaccines are produced, the spokesperson explained, “The vaccines are first supplied in either a liquid or powder form from their current primary manufacturing process and site of manufacture. 

“This so-called ‘primary bulk’ is then formulated into the ImplaVax precision engineered solid doses which have a specific size, shape, and mechanical strength using a combination of proprietary formulation and manufacturing techniques. These can include both extrusion and/or tabletting.”

The agreement culminates a busy period for the Enesi, which confirmed on September 20, 2018, its move into its new headquarters in Milton Park, Oxford.

Related news

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more